Assertio Holdings (Assertio Holdings) Intrinsic Value: Projected FCF : $4.85 (As of May. 16, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Assertio Holdings Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-16), Assertio Holdings's Intrinsic Value: Projected FCF is $4.85. The stock price of Assertio Holdings is $1.01. Therefore, Assertio Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.2.

The historical rank and industry rank for Assertio Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

ASRT' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.07 Med: 0.52 Max: 9.89
Current: 0.21

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Assertio Holdings was 9.89. The lowest was 0.07. And the median was 0.52.

ASRT's Price-to-Projected-FCF is ranked better than
99.16% of 597 companies
in the Drug Manufacturers industry
Industry Median: 1.6 vs ASRT: 0.21

Assertio Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for Assertio Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assertio Holdings Intrinsic Value: Projected FCF Chart

Assertio Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Intrinsic Value: Projected FCF

Get a 7-Day Free Trial

28.96

19.24

10.85

8.96

5.20

Assertio Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Intrinsic Value: Projected FCF	Get a 7-Day Free Trial															11.66	8.59	6.41	5.20	4.85

Competitive Comparison of Assertio Holdings's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assertio Holdings's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's Price-to-Projected-FCF falls into.

Assertio Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)

Add all the Free Cash Flow together and divide 6 will get Assertio Holdings's Free Cash Flow(6 year avg) = $37.06.

Assertio Holdings's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF	=	(Growth Multiple	*	Free Cash Flow (6 year avg)	+	Total Stockholders Equity (Mar24)	*	0.8)	/	Shares Outstanding (Diluted Average)
	=	(9.5203515959648	*	37.0616	+	134.494	*	0.8)	/	94.980
	=	4.85

Assertio Holdings (NAS:ASRT) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Assertio Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF	=	Share Price	/	Intrinsic Value: Projected FCF
	=	1.01	/	4.8477012287746
	=	0.21

Assertio Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Assertio Holdings (Assertio Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (NAS:ASRT) » Definitions » Intrinsic Value: Projected FCF

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045

Website

https://www.assertiotx.com

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Executives

Daniel A. Peisert	director, officer: President & CEO	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Paul Schwichtenberg	officer: SVP and CFO	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Ajay Patel	officer: SVP and CAO	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Sam Schlessinger	officer: SVP, General Counsel	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FORREST IL 60045
William Mckee	director
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Heather L Mason	director	100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Mark Strobeck	officer: EVP & Chief Operating Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Andrea Heslin Smiley	director	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Megan C. Timmins	officer: SVP, Gen Csl & Sec	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002